Expression of tumor necrosis factor α and its correlation with severity of oral submucous fibrosis: a case-control study

Sodhi, Sonia; Sodhi, Jasmeet Singh; Khambete, Neha; Kumar, Rahul; Marthala, Manjula; Sodhi, Neha

doi:10.1016/j.oooo.2014.02.030

Cited by 13 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Allicin has been shown to decrease tumour necrosis factor alpha (TNF-a) protein and mRNA levels, which are recognized to correlate with the severity of oral submucous fibrosis, 21 in a dosedependent manner. 22 It has also been found to suppress both the spontaneous and TNF-a-stimulated secretion of cytokines such as interleukins IL-1, IL-6, and IL-8 and leukotriene by down-regulating mRNA levels and inhibiting the activation of the nuclear factor kappa B (NF-kB) pathway.…”

Section: Discussionmentioning

confidence: 99%

Allicin as a possible adjunctive therapeutic drug for stage II oral submucous fibrosis: a preliminary clinical trial in a Chinese cohort

Jiang

Zhang

et al. 2015

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Allicin as a possible adjunctive therapeutic drug for stage II oral submucous fibrosis: a preliminary clinical trial in a Chinese cohort

Jiang

Zhang

et al. 2015

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

“…The synthesis and breakdown of extracellular matrix proteins interact intricately to promote the development of OSMF. Due to an imbalance between increased production and deposition and reduced breakdown of the components of the extracellular matrix, fibrosis results in the buildup of collagen ( 33 ). A balance of the mediators of inflammation likely plays a critical role in controlling the onset and progression of fibrosis under any fibrotic condition.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of salivary tumor necrosis factor α as a diagnostic biomarker in oral submucosal fibrosis and squamous cell carcinoma of the oral cavity and oropharynx: a cross sectional observational study

Abdul Aziz Shaikh,

Denny E,

Kumarchandra

et al. 2024

Front. Oral. Health

View full text Add to dashboard Cite

IntroductionTumor necrosis factor α (TNF-α) is known to be associated with chronic inflammation, and its expression has been shown to increase in advanced cancers. Chronic inflammation is a characteristic feature of oral submucous fibrosis (OSMF), which is a potentially malignant disorder (PMD). Squamous cell carcinoma (SCC) is associated with considerable mortality and morbidity and an early detection or monitoring would greatly help in achieving an effective cure. TNF-α was thus evaluated for use as a biomarker in the present study according to the stage of OSMF and histological grade of SCC in the oral cavity and oropharynx.MethodsThis study included 45 patients divided into 3 groups—OSMF group, SCC group and control group—each comprising 15 participants. Saliva samples were collected from each patient, and salivary TNF-α levels were estimated using an ELISA kit.ResultsStatistical analysis revealed no significant differences in TNF-α levels among the OSMF, SCC and control groups; however, there was an increase in the salivary TNF-α level in patients with stage 3 disease according to the clinical stage of OSMF, for which the p value was 0.027.DiscussionAn increase in the TNF-α concentration with increasing clinical stage suggested a role for TNF-α in the spread of OSMF involvement in anatomical structures of the oral cavity and oropharynx. No significant difference in salivary TNF-α levels was noted among the OSMF, SCC and control groups.ConclusionThe study showed a positive correlation of TNF-α with increasing stages of OSMF but was not a reliable biomarker in the categorization of the same.

show abstract

“…Allicin tend to decrease TNF-α level and inhibit cytokine production in a dose-dependent manner and thus to be used in OSF. 40,58 Salvianolic acid-B is obtained from the root of Salvia plant which significantly decreases the level of different factors contributed to the inflammation such as nitric oxide, TNF-α, Interleukin-1β (IL-1 β), ROS etc. in a doseresponsive manner and increase the expression of antiinflammatory cytokines IL-10 and transforming growth factor-β1(TGF-β1) in animal model.…”

Section: Borneolmentioning

confidence: 99%

A Review on Bucco-Adhesive Drug Delivery Systems for Oral Sub-Mucous Fibrosis: Challenges, Opportunities and Future Perspectives

Bhardwaj¹,

Tripathi²,

Mallikarjuna³

et al. 2020

Int Res J Pharm

View full text Add to dashboard Cite

Oral sub-mucous fibrosis (OSF) is a chronic, insidious disease which might affect the oral cavity (oral mucosa) including pharynx and larynx. Numerous approaches and anticancer molecules have been explored in the literature to treat OSF with different modes of action. However, complete cure for OSF is limited due to the lack of an ideal carrier for safe and effective delivery of potent drug moieties. There are several challenges such as anatomical or histological barriers and appropriate animal model need to be explored and optimized to develop the efficient treatment for oral sub-mucous fibrosis. Constant progression in the development of new formulations has led to the effective management of the disease associated with the mucosa using mucosal or muco-adhesive drug delivery systems. Muco-adhesive drug delivery systems (such as gel and patches) have gained unique position as drug cargoes. Therefore, present review is an attempt to contemplate on OSF in terms of pathogenesis, currently available treatment shaving their mode of action, major challenges encountered during treatment, usefulness/feasibility of muco-adhesive dosage forms, opportunities/future scope of muco-adhesive drug delivery in OSF and recent developments in the delivery of various anti-cancer drugs in the treatment of OSF.

show abstract

Expression of tumor necrosis factor α and its correlation with severity of oral submucous fibrosis: a case-control study

Cited by 13 publications

References 18 publications

Allicin as a possible adjunctive therapeutic drug for stage II oral submucous fibrosis: a preliminary clinical trial in a Chinese cohort

Allicin as a possible adjunctive therapeutic drug for stage II oral submucous fibrosis: a preliminary clinical trial in a Chinese cohort

Evaluation of salivary tumor necrosis factor α as a diagnostic biomarker in oral submucosal fibrosis and squamous cell carcinoma of the oral cavity and oropharynx: a cross sectional observational study

A Review on Bucco-Adhesive Drug Delivery Systems for Oral Sub-Mucous Fibrosis: Challenges, Opportunities and Future Perspectives

Contact Info

Product

Resources

About